Atrial Fibrillation is the most common arrhythmia diagnosed in clinical settings, affecting over 886,000 new people in Europe each year. By 2030, the number of people suffering from Atrial Fibrillation is expected to rise by up to 70% of the population; by 2050, Europe is expected to have the largest number of patients suffering from the condition.
In the United States, approximately 2.7 million to 6.1 million people were affected by atrial fibrillation in 2012; this number is expected to increase to 12.1 million by 2030. According to a report published in the Medical Journal of Australia in August 2015, the number of Atrial Fibrillation patients in Australia over the age of 55 was 328,562 in June 2014, and is expected to rise to over 600,000 by 2034. Such factors are expected to aid the overall Electrophysiology Devices Industry over the forecast period.
Electrophysiologists play an important role in cardiovascular health, with over 40% of cardiology encounters being related to arrhythmia. In a recent report from Wuhan, China, 16.7% of hospitalized and 44.4% of patients in an intensive care unit with COVID-19 had arrhythmias. In addition, there have been anecdotal reports of patients experiencing late myocardial dysfunction, and cardiopulmonary arrest with pulseless electrical activity or ventricular fibrillation during the recovery phase of their pulmonary illness, as well. The purpose of this joint statement from the Heart Rhythm Society, the American College of Cardiology Electrophysiology Section, and the American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology is to address various issues facing electrophysiologists (and other healthcare providers who manage arrhythmias) during the pandemic situation and to provide corresponding general guidance.
The detailed research study provides qualitative and quantitative analysis of electrophysiology devices market. The market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue across regions and further across all the major countries. The supply side analysis covers the major market players and their regional and global presence and strategies. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa and Latin America.
Key Findings of the Report:
- In the end users segment, the hospital segment will account for the highest revenue globally owing to the adoption of technologically advanced cardiac rhythm management and electrophysiological procedure devices by the interventional cardiologists at the hospitals.
- North America held the largest share in 2019 and is expected to continue the same trend over the forecast period. A company named BioSig Technologies which is a medical technology company commercialized an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced the purchase of three PURE EP Systems by St. David's HealthCare of Austin, Texas. St. David's Medical Center, an HCA Healthcare owned hospital, has been recognized with a Malcolm Baldrige National quality award which is the highest presidential honor for performance excellence.
- The major players operating in the market include Abbott, ADInstruments NZ Limited, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, GENERAL ELECTRIC COMPANY, Koninklijke Philips N.V., Medical Devices Business Services, Inc., Medtronic, MicroPort Scientific Corporation, Millar, Inc., Siemens Healthcare Private Limited, Transonic, Tyche MedTech, Inc., Vanguard AG, World Precision Instruments, Zeus Industrial Products, Inc. amongst others
Electrophysiology Devices Market:
- Access Device
- Steerable Sheath
- Transseptal Delivery System
- Pericardiocentesis Kits
- Cardiac Resynchronization Therapy Defibrillator
- Cardiac Resynchronization Therapy Pacemakers (CRT-P)
- Capital Equipment: Diagnostic
- Ultrasound Imaging System and Ultrasound Imaging Catheter
- EP Recording System
- Capital Equipment: Mapping & Navigation
- Capital Equipment: Therapy
- Defibrillators (ICD)
- Left Atrial Appendage Closure
- Pace Makers
- Remote Patient Monitoring and Diagnostic Monitoring
- Stimulators, WPI amplifiers and isolators
By Clinical Indication
- Aortic stenosis and mitral regurgitation
- Atrial Fibrillation (AF)
- Supraventricular Tachycardia
- Atrioventricular Nodal Re-entry Tachycardia (AVNRT)
- Wolff-Parkinson-White Syndrome (WPW)
- Bradycardia and Arrhythmias
By End Users
- Ambulatory Care Centers
- Diagnostic Centers
- North America
- Asia Pacific
- Middle East & Africa
- Latin America